近半年该股累计上榜龙虎榜10次，上榜次日股价平均涨1.76%，上榜后5日平均涨2.58%。 资金流向方面，今日该股主力资金净流入1.87亿元，其中，特大单净流入1.63亿元，大单资金净流入 2425.75万元。近5日主力资金净流入879.32万元。（数据宝） 昂利康今日涨停，全天换手率11.32%，成交额11.65亿元，振幅8.87%。龙虎榜数据显示，机构净买入 1.72亿元，营业部席位合计净卖出2060.64万元。 深交所公开信息显示，当日该股因日涨幅偏离值达11.39%上榜，机构专用席位净买入1.72亿元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.07亿元，其中，买入成交额为2.29亿 元，卖出成交额为7742.32万元，合计净买入1.52亿元。 具体来看，今日上榜的营业部中，共有6家机构专用席位现身，即买一、买二、买三、买四、买五、卖 一、卖五，合计买入金额2.05亿元，卖出金额3235.10万元，合计净买入1.72亿元。 昂利康7月31日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | ...

Group 1 - The company, Anglikang (002940.SZ), has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration [1] - Sitagliptin Metformin Extended-Release Tablets are a compound preparation suitable for adult patients with type 2 diabetes who are currently receiving combined treatment with Sitagliptin and Metformin Extended-Release Tablets [1]

昂利康（002940）(002940.SZ)公告，公司收到国家药品监督管理局签发的西格列汀二甲双胍缓释片 《药品注册证书》。西格列汀二甲双胍缓释片为复方制剂，适用于正在接受西格列汀和二甲双胍缓释片 联合治疗的成人2型糖尿病患者。 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-056 浙江昂利康制药股份有限公司 关于获得药品注册证书的公告 三、对公司的影响 本次西格列汀二甲双胍缓释片获得药品注册证书，将进一步丰富公司产品管 线。由于医药行业的特殊性，药品的销售容易受到国家政策、市场环境变化等因 素影响，具体销售情况存在较大不确定性。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的西格列汀二甲双胍缓释片《药品注 册证书》，现将有关情况公告如下： | 药品通用名称 | 西格列汀二甲双胍缓释片 | | --- | --- | | 主要成份 | 磷酸西格列汀和盐酸二甲双胍 | | 剂型 | 片剂 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 3 类 | | 规格 | 磷酸西格列汀 50mg（按 C₁₆H₁₅F₆N₅O 计）与盐酸二甲 | | | 双胍 500mg | | 受理号 | CYHS2400188、CYHB2500250 | | 药品 ...

| | 买入金额最大的前5名 | | | | | | --- | --- | --- | --- | --- | --- | | 序号 | | 交易营业部名称 | | 买入金额(万) | 占总成交比例 | | 1 | 机构专用 | | 1414次 43.42% 2 | 8269.79 | 7.10% | | 2 | 机构专用 | Castmoney.com | 1414次 43.42% b | 3797.68 | 3.26% | | 3 | 机构专用 | | 1414次 43.42% | 3490.92 | 3.00% | | 4 | 机构专用 | | 1414次 43.42% | 2990.94 | 2.57% | | 5 | 机构专用 | | 1414次 43.42% | 1913.61 | 1.64% | | | 卖出金额最大的前5名 | | | | | | 序号 | 交易营业部名称 | | 买入金额(万) | 占总成交比例 | | --- | --- | --- | --- | --- | | 1 | 机构专用 | 1414次 43.42% 2 | 3490.92 | 3.00% | | 2 | 中信 ...

昂利康今日涨10.00%，成交额11.65亿元，换手率11.32%，盘后龙虎榜数据显示，5家机构专用席位净买 入1.84亿元，有1家机构专用席位净卖出1147.94万元。 ...

7月31日，A股三大指数全天震荡下行，截至收盘，沪指跌1.18%，深证成指跌1.73%，创业板指跌1.66%。 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 上证指数 | | | 3573.21c | | -42.51 - -1.18% | | 399001 | 深证成指 | 11009.77c -193.26 | | | -1.73% | | 399006 | 创业板指 | Concession of the control of -39.37 | 2328.31 c | | -1.66% | 沪深两市全天成交额1.94万亿，较上个交易日放量917亿。全市场超4200只个股下跌。 盘面上，钢铁、能源金属、煤炭开采加工、光伏设备、影视院线板块走低，液冷服务器板块涨幅居前，智谱AI、辅助 生殖、小红书概念表现强势。 具体来看，创新药概念延续强势，南新制药、安科生物、奥翔药业、昂利康等9股封板。 液冷服务器概念全天强势，英维克、思泉新材、大元泵业、冰轮环境等多股涨停。 | 代码 | 名称 | 涨幅� ...

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a significant rebound, with numerous stocks doubling in value and a strong performance from innovative drug companies, indicating a potential for continued growth and investment opportunities [1][2][3]. Group 1: Market Performance - As of July 29, 2023, the pharmaceutical sector has seen 42 stocks double in value this year, with Shuyatain leading at a 560% increase [1]. - Eight stocks, including Saifen Technology and Yipin Hong, have risen over 200%, while over 30 stocks have increased by more than 100% [1]. Group 2: Fund Performance - The surge in the pharmaceutical sector has led to significant gains in several pharmaceutical-themed funds, with many achieving over 100% returns in the past year [2]. - Fund managers believe that innovative drugs are likely to gain traction due to high demand and the upcoming product launches from various A-share and H-share companies [2]. Group 3: Industry Insights - Analysts highlight that the innovative drug sector is entering a golden development phase, supported by short-term performance from research outcomes and long-term benefits from aging populations and health demand upgrades [2]. - The innovative drug sector is seen as the most promising sub-industry within pharmaceuticals, with a clear growth trajectory and investment potential [3]. Group 4: Future Outlook - The innovative drug sector is expected to benefit from a combination of policy support and fundamental growth, leading to a revaluation of the sector [3]. - Analysts recommend continued investment in specific segments such as CRO & CDMO, GLP-1, and unique raw materials, which are anticipated to show strong performance [3].

证券代码：002940 证券简称：昂利康 公告编号：2025-055 浙江昂利康制药股份有限公司 关于获得药品注册证书的公告 1 监局批准。根据国家相关政策规定，本次获得《药品注册证书》视同通过一致性 评价。 三、对公司的影响 本次美索巴莫注射液获得药品注册证书，将进一步丰富公司产品管线。由于 医药行业的特殊性，药品的销售容易受到国家政策、市场环境变化等因素影响， 具体销售情况存在较大不确定性。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的美索巴莫注射液《药品注册证书》， 现将有关情况公告如下： | 美索巴莫注射液 | | 药品通用名称 | | --- | --- | --- | | 美索巴莫 | | 主要成份 | | 注射剂 | | 剂型 | | 药品注册（境内生产） | | 申请事项 | | 化学药品 | 3 类 | 注册分类 | | 10ml：1g | | 规格 | | CYHS2401003 | | 受理号 | | 国药准字 | H20254 ...

Core Insights - The report maintains a positive outlook on small molecule drug conjugates (SMDCs) and related companies, highlighting their potential in cancer treatment due to their ability to enhance efficacy while reducing toxicity [1][5][17] - The report emphasizes the clinical advantages of SMDCs, including better tumor penetration, reduced toxicity to normal cells, and easier control over synthesis and costs compared to antibody-drug conjugates (ADCs) [5][11][12] - The report identifies domestic biopharmaceutical companies, particularly Affinivax, as leaders in the SMDC space, showcasing significant advancements in innovative cancer drug development [5][12][17] Industry Overview - The pharmaceutical and biotechnology sector has shown a relative price-to-earnings (P/E) ratio of 51.14 as of July 25, 2025, which is significantly higher than its historical low of 24.38, indicating a premium valuation compared to the broader market [19] - The report notes that the healthcare sector's valuation is 279% higher than the Shanghai Composite Index, reflecting strong investor interest and confidence in the industry [19] - Recent market performance indicates a 1.90% increase in the pharmaceutical and biotechnology sector from July 21 to July 25, 2025, ranking it 16th among 27 sub-industries [26][29] Company Focus - The report suggests monitoring companies involved in the SMDC space, including Affinivax, and those collaborating with them, such as Innovent Biologics and others, which are expected to benefit from the growing interest in innovative cancer therapies [5][17][18] - Specific companies highlighted for their innovative drug development capabilities include Innovent Biologics, Shunyi Pharmaceutical, and others, which are positioned to capitalize on the advancements in SMDC technology [5][18]